WO2021054534A3 - Stabilized efinaconazole-containing pharmaceutical composition comprising combination of chelating agent and antioxidant - Google Patents

Stabilized efinaconazole-containing pharmaceutical composition comprising combination of chelating agent and antioxidant Download PDF

Info

Publication number
WO2021054534A3
WO2021054534A3 PCT/KR2019/017072 KR2019017072W WO2021054534A3 WO 2021054534 A3 WO2021054534 A3 WO 2021054534A3 KR 2019017072 W KR2019017072 W KR 2019017072W WO 2021054534 A3 WO2021054534 A3 WO 2021054534A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
combination
antioxidant
chelating agent
containing pharmaceutical
Prior art date
Application number
PCT/KR2019/017072
Other languages
French (fr)
Korean (ko)
Other versions
WO2021054534A2 (en
Inventor
김범준
구교탄
Original Assignee
주식회사 바이오빌리프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 바이오빌리프 filed Critical 주식회사 바이오빌리프
Publication of WO2021054534A2 publication Critical patent/WO2021054534A2/en
Publication of WO2021054534A3 publication Critical patent/WO2021054534A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides an efinaconazole-containing solution-type topically-administered pharmaceutical composition comprising: a combination of diethylene glycol monoethyl ether and isopropyl myristate as a nonvolatile solvent; and a specific combination of a chelating agent and an antioxidant. The pharmaceutical composition of the present invention has excellent physicochemical stability.
PCT/KR2019/017072 2019-09-17 2019-12-05 Stabilized efinaconazole-containing pharmaceutical composition comprising combination of chelating agent and antioxidant WO2021054534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0113976 2019-09-17
KR1020190113976A KR20210032665A (en) 2019-09-17 2019-09-17 Stabilized efinaconazole-containing pharmaceutical compositions comprising a combination of chelating agent and acid

Publications (2)

Publication Number Publication Date
WO2021054534A2 WO2021054534A2 (en) 2021-03-25
WO2021054534A3 true WO2021054534A3 (en) 2021-05-14

Family

ID=74884654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017072 WO2021054534A2 (en) 2019-09-17 2019-12-05 Stabilized efinaconazole-containing pharmaceutical composition comprising combination of chelating agent and antioxidant

Country Status (2)

Country Link
KR (1) KR20210032665A (en)
WO (1) WO2021054534A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20140072016A (en) * 2011-06-24 2014-06-12 아쿠아 바이오 테크놀로지 에이에스에이 Methods for the production of a cosmetic composition from hatching fluid and uses thereof for improving the cosmetic appearance of skin
KR20160068812A (en) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 Stabilized efinaconazole compositions
KR20160087898A (en) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 Anti-infective methods, compositions, and devices
WO2018110693A1 (en) * 2016-12-16 2018-06-21 株式会社カネカ Onychomycosis therapeutic agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20140072016A (en) * 2011-06-24 2014-06-12 아쿠아 바이오 테크놀로지 에이에스에이 Methods for the production of a cosmetic composition from hatching fluid and uses thereof for improving the cosmetic appearance of skin
KR20160068812A (en) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 Stabilized efinaconazole compositions
KR20160087898A (en) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 Anti-infective methods, compositions, and devices
WO2018110693A1 (en) * 2016-12-16 2018-06-21 株式会社カネカ Onychomycosis therapeutic agent

Also Published As

Publication number Publication date
KR20210032665A (en) 2021-03-25
WO2021054534A2 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
EP4257185A3 (en) Gip/glp1 agonist compositions
MX2021005714A (en) New heterocyclic compounds.
MX2020006612A (en) Compound functioning as bromodomain protein inhibitor, and composition.
EP3898922A4 (en) Solvent compositions containing 1,2,2-trifluoro-1-trifluoromethylcyclobutane (tfmcb)
MX2018006800A (en) Pharmaceutical composition.
CR20200285A (en) Anti-cd40 antibody drug conjugates
EP4289478A3 (en) Edaravone pharmaceutical composition
CO2019002555A2 (en) Pharmaceutical composition
EP3917778A4 (en) Low volatile tackifier compositions
MX2020011756A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same.
MX2019010330A (en) Formulations with improved stability.
TR199902034T2 (en) Nimesilide gel systems for external use.
WO2021054534A3 (en) Stabilized efinaconazole-containing pharmaceutical composition comprising combination of chelating agent and antioxidant
MX2021010022A (en) Pharmaceutical composition.
MX2020011504A (en) Pharmaceutical composition comprising salbutamol.
MX2023000926A (en) Novel pyrazole derivatives.
PH12021550017A1 (en) Ivosidenib forms and pharmaceutical compositions
EP4037665A4 (en) Compositions comprising pedf-derived short peptides (pdsp) and uses thereof
PH12020500674A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
WO2021054536A3 (en) Stabilized pharmaceutical composition comprising epinaconazole
MX2022006711A (en) New braf inhibitors as paradox breakers.
MX2021012852A (en) Method for preparing stable peptide formulations.
WO2021054531A3 (en) Stabilized efinaconazole-containing pharmaceutical composition comprising antioxidant
MX2022011593A (en) Crystalline forms of a tyk2 inhibitor.
MX2022002667A (en) Ophthalmic composition for the treatment of uveitis.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19946103

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19946103

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 13/09/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 19946103

Country of ref document: EP

Kind code of ref document: A2